Clinical Trial Update: Intravenous Ketamine for Treatment-Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intravenous ketamine for treatment-resistant depression is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Mayo Clinic | Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD) | Phase 2 | Status: RECRUITING